Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 14, 2013 - Issue 7-8
Submit an article Journal homepage
727
Views
66
CrossRef citations to date
0
Altmetric
Clinical trial-animal

Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis

Erin J. McAllumDepartment of Pathology
,
Nastasia K.-H. LimDepartment of Pathology
,
James L. HickeySchool of Chemistry;Bio21 Molecular Science and Biotechnology Institute
,
Brett M. PatersonSchool of Chemistry;Bio21 Molecular Science and Biotechnology Institute
,
Paul S. DonnellySchool of Chemistry;Bio21 Molecular Science and Biotechnology Institute
,
Qiao-Xin LiFlorey Institute of Neuroscience and Mental Health
,
Jeffrey R. LiddellDepartment of Pathology
,
Kevin J. Barnham
,
Anthony R. WhiteDepartment of Pathology;Florey Institute of Neuroscience and Mental Health
&
Peter J. CrouchDepartment of Pathology;Florey Institute of Neuroscience and Mental HealthCorrespondence[email protected]
 show all
Pages 586-590 | Received 29 May 2013, Accepted 07 Jul 2013, Published online: 19 Aug 2013

References

  • Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
  • Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–31.
  • Soon CP, Donnelly PS, Turner BJ, Hung LW, Crouch PJ, Sherratt NA, et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem. 2011;286:44035–44.
  • Fodero-Tavoletti MT, Villemagne VL, Paterson BM, White AR, Li QX, Camakaris J, et al. Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer’s disease. J Alzheimers Dis. 2010;20:49–55.
  • Hung LW, Villemagne VL, Cheng L, Sherratt NA, Ayton S, White AR, et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease. The Journal of Experimental Medicine. 2012;209:837–54.
  • Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14:1105–16.
  • Blower PJ, Castle TC, Cowley AR, Dilworth JR, Donnelly PS, Labisbal E, et al. Structural trends in copper(II) bis (thiosemicarbazone) radiopharmaceuticals. Dalton Transactions. 2003; 4416–25.
  • Gingras BA, Suprunchuk T, Bayley CH. The preparation of some thiosemicarbazones and their copper complexes: Part III. Canadian Journal of Chemistry. 1962;40:1053–9.
  • Padi P, Ganta M, Bollikonda S, Chaganti S, Akula R, Dommati L. Process for preparing riluzole. 2008. US 20080108827. United States of America.
  • Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39:147–57.
  • Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998;50:62–6.
  • Snow RJ, Turnbull J, da Silva S, Jiang F, Tarnopolsky MA. Creatine supplementation and riluzole treatment provide similar beneficial effects in copper/zinc superoxide dismutase (G93A) transgenic mice. Neuroscience. 2003;119:661–7.
  • Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol. 2004;251: 1080–4.
  • Crow JP, Calingasan NY, Chen J, Hill JL, Beal MF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol. 2005;58:258–65.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.